MPS Powered by Eureka

Submission Tilte

Current Progress in Protein Degradation and Cancer Therapy

Submission Abstract:

Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the development of cancer therapy. The main focus of TPD is the development of heterobifunctional small molecules degraders, including proteolysis-targeting chimeras (PROTACs), which contain two linked moieties with one binding the protein of interest and the other binding an E3 ligase, the formation of that complex results in polyubiquitination of the protein of interest and its subsequent degradation by the 26S proteasome. In the realm of cancer therapy, a profound evolution has ushered in sophisticated strategies that encompass both traditional protein degradation and antibody-drug conjugate for targeted delivery of degraders.